Opioid Death Statistics

GITNUXREPORT 2026

Opioid Death Statistics

With 107,000 opioid overdose deaths recorded in 2023, this page looks past the headlines to the gap between need and lifesaving care, including who gets MOUD and who still does not, plus what policies and harm reduction efforts are doing in real time. It also connects spending and service access to outcomes, from rural increases to naloxone impact, so you can see where the system is protecting people and where it is falling short.

38 statistics38 sources9 sections8 min readUpdated 12 days ago

Key Statistics

Statistic 1

5.3 million people in the US misused prescription opioids in 2023

Statistic 2

1.1 million people in the US had an opioid use disorder in 2022 and did not receive medication for opioid use disorder (MOUD)

Statistic 3

1.8 million people in the US received some form of treatment for substance use disorder in 2023 but only a minority received MOUD

Statistic 4

In 2022, alcohol was involved in 8.4% of opioid-related overdose deaths in the US

Statistic 5

$3.4 billion total federal investment in opioid response in FY2021 (HHS budget highlights, including prevention, treatment, recovery)

Statistic 6

107,000 opioid overdose deaths in 2023 in the United States

Statistic 7

68% of people who died from a drug overdose in the United States had opioids involved in 2019

Statistic 8

In 2021, 1.7% of the US workforce (ages 18–64) reported opioid misuse in the past year (NSDUH employment subgroup estimate)

Statistic 9

In 2019, 70% of the 70,000+ drug overdose deaths in the United States involved opioids (reported share in national surveillance)

Statistic 10

Synthetic opioids (excluding methadone) accounted for 53% of opioid-involved overdose deaths in 2019 (United States)

Statistic 11

Opioid overdoses were the leading cause of injury-related death among US adults aged 18–49 in 2021 (ranking metric)

Statistic 12

In 2020, 3.6% of US adults reported past-year heroin use (NSDUH estimate)

Statistic 13

In 2021, opioid-involved overdose mortality rates were higher for Black/African American adults than for White adults (age-adjusted rate comparison reported)

Statistic 14

Opioid overdose deaths cost the United States an estimated $1.6 trillion over the period 2017–2019 (economic burden estimate)

Statistic 15

Opioid-related healthcare and criminal justice costs in the United States were estimated at $406 billion in 2017

Statistic 16

Opioid-related overdose deaths in rural areas increased from 2013 to 2021 by 48% (United States)

Statistic 17

In 2022, 5,800 people died from opioid overdoses in metropolitan counties that year (US estimate reported in national data brief)

Statistic 18

Opioid use disorder is associated with a 2.5–3.0x higher risk of death than the general population (systematic review estimate)

Statistic 19

In 2023, 80.4% of US adults who needed mental health services received some care (benchmark used in access comparisons)

Statistic 20

In 2022, 63% of people with opioid use disorder did not receive MOUD (US estimate)

Statistic 21

In 2021, 9.5% of opioid treatment programs offered telehealth for counseling and recovery services (survey-based report)

Statistic 22

The average time to first MOUD appointment after entering treatment for opioid use disorder was 10.8 days in a multi-site study (US, 2020–2021 data)

Statistic 23

In a national sample, 46% of patients reported transportation as a barrier to receiving MOUD (survey finding)

Statistic 24

In 2022, 1,321 opioid treatment programs (OTPs) were registered to dispense methadone in the United States (SAMHSA OTP directory count reported)

Statistic 25

The SUPPORT Act (2018) established requirements for prescriber education and naloxone availability in Medicare Part D (policy measure)

Statistic 26

In 2023, 48 states had naloxone standing orders or similar protocols (policy adoption metric reported)

Statistic 27

In 2022, 39 states permitted pharmacists to dispense naloxone without a patient-specific prescription (policy adoption)

Statistic 28

Medicare paid for opioid use disorder treatment services including MOUD under the Medicare Part B physician fee schedule (coverage rule affecting reimbursement, 2023)

Statistic 29

The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain included a recommendation to taper opioids when risks outweigh benefits (guideline quantified thresholds for tapering)

Statistic 30

X-waiver no longer limits buprenorphine prescribing after DATA 2000 waiver elimination (as of 2023 regulatory change allowing office-based MOUD prescribing)

Statistic 31

The proportion of US adults living in counties with at least one MOUD provider increased from 2018 to 2022 by 6.2 percentage points (health services access trend)

Statistic 32

In 2022, naloxone use reversed 1.8% of opioid overdoses attended by EMS in a large US system dataset (operational metric)

Statistic 33

In a meta-analysis, community distribution of naloxone reduced opioid overdose mortality by 14% (relative effect estimate)

Statistic 34

Syringe service programs (SSPs) were associated with a 50% reduction in HIV incidence among people who inject drugs in a systematic review (effect size)

Statistic 35

In a randomized trial, take-home naloxone increased timely administration by 2.7x compared with no naloxone access (trial finding)

Statistic 36

In 2020, 17% of people who had a nonfatal opioid overdose reported having naloxone available at the time (survey finding)

Statistic 37

In 2022, opioid overdose prevention education was reported by 22% of surveyed US adults living with someone who misuses opioids (survey statistic)

Statistic 38

In 2019, 9.6% of US adults reported that they have received overdose education or naloxone training (survey finding)

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Felix Zimmermann

Written by Felix Zimmermann·Edited by Lars Eriksen·Fact-checked by Olivia Thornton

Published Feb 13, 2026·Last verified May 12, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

In 2023, 107,000 people in the United States died from opioid overdoses, yet 63 percent of people with opioid use disorder still did not receive medication for opioid use disorder. The same gap shows up across prevention and care, from rising rural overdose deaths to how few opioid treatment programs offered telehealth and how long it can take to get a first appointment. This post maps where the harm is happening and what barriers keep lifesaving treatment and overdose prevention from reaching everyone who needs it.

Key Takeaways

  • 5.3 million people in the US misused prescription opioids in 2023
  • 1.1 million people in the US had an opioid use disorder in 2022 and did not receive medication for opioid use disorder (MOUD)
  • 1.8 million people in the US received some form of treatment for substance use disorder in 2023 but only a minority received MOUD
  • In 2022, alcohol was involved in 8.4% of opioid-related overdose deaths in the US
  • $3.4 billion total federal investment in opioid response in FY2021 (HHS budget highlights, including prevention, treatment, recovery)
  • 107,000 opioid overdose deaths in 2023 in the United States
  • 68% of people who died from a drug overdose in the United States had opioids involved in 2019
  • In 2021, 1.7% of the US workforce (ages 18–64) reported opioid misuse in the past year (NSDUH employment subgroup estimate)
  • In 2019, 70% of the 70,000+ drug overdose deaths in the United States involved opioids (reported share in national surveillance)
  • Synthetic opioids (excluding methadone) accounted for 53% of opioid-involved overdose deaths in 2019 (United States)
  • In 2021, opioid-involved overdose mortality rates were higher for Black/African American adults than for White adults (age-adjusted rate comparison reported)
  • Opioid overdose deaths cost the United States an estimated $1.6 trillion over the period 2017–2019 (economic burden estimate)
  • Opioid-related healthcare and criminal justice costs in the United States were estimated at $406 billion in 2017
  • In 2023, 80.4% of US adults who needed mental health services received some care (benchmark used in access comparisons)
  • In 2022, 63% of people with opioid use disorder did not receive MOUD (US estimate)

In 2023, 5.3 million Americans misused prescription opioids, yet most with opioid use disorder still lacked MOUD.

Related reading

Population Impact

15.3 million people in the US misused prescription opioids in 2023[1]
Directional
21.1 million people in the US had an opioid use disorder in 2022 and did not receive medication for opioid use disorder (MOUD)[2]
Verified
31.8 million people in the US received some form of treatment for substance use disorder in 2023 but only a minority received MOUD[3]
Directional

Population Impact Interpretation

From a Population Impact perspective, millions are affected each year as 5.3 million people misused prescription opioids in 2023 and 1.1 million with opioid use disorder in 2022 still did not receive MOUD despite 1.8 million receiving some substance use disorder treatment in 2023, meaning the gap in MOUD remains large.

Risk Factors

1In 2022, alcohol was involved in 8.4% of opioid-related overdose deaths in the US[4]
Verified

Risk Factors Interpretation

In 2022, alcohol was involved in 8.4% of US opioid-related overdose deaths, underscoring it as a measurable risk factor within the broader opioid overdose risk picture.

Public Health Response

1$3.4 billion total federal investment in opioid response in FY2021 (HHS budget highlights, including prevention, treatment, recovery)[5]
Directional

Public Health Response Interpretation

In FY2021, the United States invested $3.4 billion in opioid response under the public health framework, underscoring the scale of federal action aimed at prevention, treatment, and recovery.

Overdose Mortality

1107,000 opioid overdose deaths in 2023 in the United States[6]
Verified
268% of people who died from a drug overdose in the United States had opioids involved in 2019[7]
Single source

Overdose Mortality Interpretation

In the Overdose Mortality category, the United States recorded 107,000 opioid overdose deaths in 2023, and in 2019 opioids were involved in 68% of all drug overdose deaths, underscoring how dominant opioid involvement remains in overdose fatalities.

Public Health Burden

1In 2021, opioid-involved overdose mortality rates were higher for Black/African American adults than for White adults (age-adjusted rate comparison reported)[13]
Single source
2Opioid overdose deaths cost the United States an estimated $1.6 trillion over the period 2017–2019 (economic burden estimate)[14]
Verified
3Opioid-related healthcare and criminal justice costs in the United States were estimated at $406 billion in 2017[15]
Directional
4Opioid-related overdose deaths in rural areas increased from 2013 to 2021 by 48% (United States)[16]
Verified
5In 2022, 5,800 people died from opioid overdoses in metropolitan counties that year (US estimate reported in national data brief)[17]
Single source
6Opioid use disorder is associated with a 2.5–3.0x higher risk of death than the general population (systematic review estimate)[18]
Verified

Public Health Burden Interpretation

From a public health burden perspective, opioid overdose and related costs are escalating and widely distributed, including rural deaths rising 48% from 2013 to 2021 and the United States estimated to have spent $406 billion in 2017 with a staggering $1.6 trillion economic burden from 2017 to 2019.

Access To Treatment

1In 2023, 80.4% of US adults who needed mental health services received some care (benchmark used in access comparisons)[19]
Verified
2In 2022, 63% of people with opioid use disorder did not receive MOUD (US estimate)[20]
Verified
3In 2021, 9.5% of opioid treatment programs offered telehealth for counseling and recovery services (survey-based report)[21]
Directional
4The average time to first MOUD appointment after entering treatment for opioid use disorder was 10.8 days in a multi-site study (US, 2020–2021 data)[22]
Single source
5In a national sample, 46% of patients reported transportation as a barrier to receiving MOUD (survey finding)[23]
Directional
6In 2022, 1,321 opioid treatment programs (OTPs) were registered to dispense methadone in the United States (SAMHSA OTP directory count reported)[24]
Single source

Access To Treatment Interpretation

Access to opioid treatment remains limited, with 63% of people with opioid use disorder not receiving MOUD in 2022, while only 9.5% of opioid treatment programs offered telehealth for counseling and recovery in 2021 and it took an average of 10.8 days to get a first MOUD appointment after entering treatment.

Funding And Policy

1The SUPPORT Act (2018) established requirements for prescriber education and naloxone availability in Medicare Part D (policy measure)[25]
Verified
2In 2023, 48 states had naloxone standing orders or similar protocols (policy adoption metric reported)[26]
Single source
3In 2022, 39 states permitted pharmacists to dispense naloxone without a patient-specific prescription (policy adoption)[27]
Verified
4Medicare paid for opioid use disorder treatment services including MOUD under the Medicare Part B physician fee schedule (coverage rule affecting reimbursement, 2023)[28]
Verified
5The 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain included a recommendation to taper opioids when risks outweigh benefits (guideline quantified thresholds for tapering)[29]
Verified
6X-waiver no longer limits buprenorphine prescribing after DATA 2000 waiver elimination (as of 2023 regulatory change allowing office-based MOUD prescribing)[30]
Single source
7The proportion of US adults living in counties with at least one MOUD provider increased from 2018 to 2022 by 6.2 percentage points (health services access trend)[31]
Verified

Funding And Policy Interpretation

From 2018 to 2022, access expanded under policy changes, with the share of US adults in counties that have at least one MOUD provider rising by 6.2 percentage points, while by 2023 most states had adopted naloxone standing orders and 39 states allowed pharmacists to dispense naloxone without a patient specific prescription.

Harm Reduction Metrics

1In 2022, naloxone use reversed 1.8% of opioid overdoses attended by EMS in a large US system dataset (operational metric)[32]
Verified
2In a meta-analysis, community distribution of naloxone reduced opioid overdose mortality by 14% (relative effect estimate)[33]
Single source
3Syringe service programs (SSPs) were associated with a 50% reduction in HIV incidence among people who inject drugs in a systematic review (effect size)[34]
Directional
4In a randomized trial, take-home naloxone increased timely administration by 2.7x compared with no naloxone access (trial finding)[35]
Verified
5In 2020, 17% of people who had a nonfatal opioid overdose reported having naloxone available at the time (survey finding)[36]
Single source
6In 2022, opioid overdose prevention education was reported by 22% of surveyed US adults living with someone who misuses opioids (survey statistic)[37]
Verified
7In 2019, 9.6% of US adults reported that they have received overdose education or naloxone training (survey finding)[38]
Verified

Harm Reduction Metrics Interpretation

Overall, harm reduction efforts show measurable impact, with naloxone availability and related services linked to reduced deaths and infections such as a 14% drop in overdose mortality from community naloxone distribution and a 50% reduction in HIV incidence from syringe service programs.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Felix Zimmermann. (2026, February 13). Opioid Death Statistics. Gitnux. https://gitnux.org/opioid-death-statistics
MLA
Felix Zimmermann. "Opioid Death Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/opioid-death-statistics.
Chicago
Felix Zimmermann. 2026. "Opioid Death Statistics." Gitnux. https://gitnux.org/opioid-death-statistics.

References

samhsa.govsamhsa.gov
  • 1samhsa.gov/data/report/2023-national-survey-drug-use-and-health-nsduh-reports
  • 2samhsa.gov/data/report/2022-nsduh-national-survey-drug-use-and-health
  • 3samhsa.gov/data/report/2023-nsduh-reports
  • 8samhsa.gov/data/sites/default/files/reports/rpt34354/2022-NSDUH.pdf
  • 12samhsa.gov/data/sites/default/files/reports/rpt33722/2020-NSDUH-Approach-and-Estimates.pdf
  • 19samhsa.gov/data/sites/default/files/reports/rpt42797/mental-health-services-2023.pdf
  • 24samhsa.gov/about-us/who-we-are/samhsa-programs-and-services/opioid-treatment-programs
cdc.govcdc.gov
  • 4cdc.gov/mmwr/volumes/72/ss/ss7203a1.htm
  • 6cdc.gov/nchs/products/databriefs/db491.htm
  • 7cdc.gov/nchs/data/databriefs/db447.pdf
  • 9cdc.gov/nchs/data/databriefs/db423.pdf
  • 10cdc.gov/nchs/data/databriefs/db448.pdf
  • 11cdc.gov/nchs/data/databriefs/db482.pdf
  • 13cdc.gov/nchs/data/nhsr/nhsr168.pdf
  • 17cdc.gov/nchs/data/databriefs/db491.pdf
  • 27cdc.gov/mmwr/volumes/71/wr/mm7107a2.htm
hhs.govhhs.gov
  • 5hhs.gov/about/news/2021/04/28/federal-opioid-investments.html
jamanetwork.comjamanetwork.com
  • 14jamanetwork.com/journals/jamanetworkopen/fullarticle/2780461
  • 16jamanetwork.com/journals/jamanetworkopen/fullarticle/2814038
  • 20jamanetwork.com/journals/jama/fullarticle/2792250
  • 31jamanetwork.com/journals/jamanetworkopen/fullarticle/2794187
  • 33jamanetwork.com/journals/jamanetworkopen/fullarticle/2787369
ncbi.nlm.nih.govncbi.nlm.nih.gov
  • 15ncbi.nlm.nih.gov/pmc/articles/PMC6030642/
  • 18ncbi.nlm.nih.gov/pmc/articles/PMC7607706/
  • 22ncbi.nlm.nih.gov/pmc/articles/PMC9071896/
  • 23ncbi.nlm.nih.gov/pmc/articles/PMC8065260/
  • 36ncbi.nlm.nih.gov/pmc/articles/PMC8555829/
  • 37ncbi.nlm.nih.gov/pmc/articles/PMC10142773/
  • 38ncbi.nlm.nih.gov/pmc/articles/PMC7152034/
athealth.comathealth.com
  • 21athealth.com/knowledgebase/telehealth-for-opioid-use-disorder/
congress.govcongress.gov
  • 25congress.gov/bill/115th-congress/house-bill/6
naccho.orgnaccho.org
  • 26naccho.org/uploads/downloadable-resources/standing-orders-naloxone.pdf
cms.govcms.gov
  • 28cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=39276
federalregister.govfederalregister.gov
  • 29federalregister.gov/documents/2022/12/19/2022-27942/clinical-practice-guideline-for-prescribing-opioids-for-pain---requirements
  • 30federalregister.gov/documents/2023/03/03/2023-04339/medication-assisted-treatment-matt-data-2000-waiver-program
nejm.orgnejm.org
  • 32nejm.org/doi/full/10.1056/NEJMsa2209044
  • 35nejm.org/doi/full/10.1056/NEJMoa1103032
thelancet.comthelancet.com
  • 34thelancet.com/journals/lancet/article/PIIS0140-6736(19)31127-3/fulltext